Anavex Life Sciences

Anavex Life Sciences shares rise after FDA gives green light on Phase 2 trial

Its drug Anavex2-73 is being developed to treat Rett Syndrome, a rare neurological disorder that occurs mainly in girls and can lead to severe impairments

Scientists sitting in a lab
The biopharma will proceed with a double-blind, randomized Phase 2 study

Anavex Life Sciences Corp (NASDAQ: AVXL) shares are on the rise following the US Food and Drug Administration’s approval of its Investigational New Drug application for its Phase 2 trial of its drug Anavex2-73 for the treatment of Rett Syndrome.

Rett Syndrome is a rare, non-inherited neurological disorder that occurs mainly in girls and can lead to severe impairments, including losing the ability to speak, walk, eat and breathe.

READ: Why Viking Therapeutics isn’t waiting for a white knight

“The acceptance of this IND by the FDA is a significant milestone for Anavex2-73,” stated CEO Christopher U. Missling in the company’s press release.

“This is an important step toward achieving clinical data for the third indication for Anavex2-73 also incorporating genomic precision medicine biomarkers.”

Shares of the New York-based biopharmaceutical company jumped nearly 14% to $2.81 in Friday morning trading.

Anavex will proceed with a double-blind, randomized Phase 2 study using Anavex2-73 for the treatment of patients with Rett syndrome.

The company also has clinical development programs for the drug for the treatment of Alzheimer’s disease and Parkinson’s disease dementia.


Contact Lenore Fedow at [email protected]

Follow her on Twitter@LenoreMariee

Quick facts: Anavex Life Sciences

Price: $2.71

Market: NASDAQ
Market Cap: $142.68 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Arcadia Biosciences makes major progress on its hemp venture...

Arcadia Biosciences Inc (NASDAQ:RKDA) CEO Raj Ketkar tells Proactive the California-based company expects to “significantly scale revenues in 2020” as it reported financial and business results for the second quarter and first half of 2019. Ketkar says the agricultural innovation company made...

1 day, 9 hours ago

2 min read